Overview

Zymeworks has developed a number of proprietary platform technologies to enable the development of next-generation therapeutics. These platforms allow for the targeting of differentiated biological pathways leading to the internal and partnered development of novel therapies in a number of different indications. Our platform technologies include:

Bispecific antibodies developed using the Azymetric™ platform resemble conventional monospecific antibodies while being able to simultaneously bind to two different targets resulting in additive or synergistic therapeutic responses. Azymetric™ antibodies spontaneously assemble into a single molecule with two different Fab domains comprising of unique heavy and light chain pairings. Azymetric™ antibodies are manufactured using conventional monoclonal antibody processes and can also be easily adapted to rapidly screen target and sequence combinations for bispecific activities in the final therapeutic format thereby significantly reducing drug development timelines.

ZymeLink™, a next-generation ADC platform, is a suite of proprietary cytotoxins (cell-killing compounds), stable linkers, and conjugation technologies. ZymeLink™ is compatible with traditional antibodies, proteins, and the Azymetric™ bispecific antibody platform, creating multifunctional therapeutics designed to overcome the limitations of existing ADCs.

The Effector Function Enhancement and Control Technology (EFECT™) platform is a library of antibody Fc modifications engineered to modulate the activity of the antibody-mediated immune response, which includes both the up and down-regulation of effector functions. This platform is compatible with traditional monoclonal as well as Azymetric™ bispecific antibodies to further enable the customization of therapeutic responses for different diseases.